Physician profile
Lawrence R Dardick
NPI 1205891603
$1,113.16
in general payments reported to CMS, 2019-2025
18 companies · $224 in 2025
The $224 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $137 · 2020: $16.11 · 2021: $48.19 · 2022: $71.67 · 2023: $250 · 2024: $366 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $840.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $839.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Siemens Medical Solutions USA, INC. | $171.22 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $145.17 | 2025 | |
| Reflexion Medical, INC. | $124.98 | 2022-2025 | Reflexion Medical Radiotherapy System |
| Kite Pharma, INC. | $101.15 | 2019 | |
| Boston Scientific Corporation | $89.63 | 2021-2024 | Spaceoar System |
| Novartis Pharmaceuticals Corporation | $83.63 | 2024-2025 | |
| Janssen Biotech, INC. | $45.96 | 2021-2023 | Erleada |
| Regeneron Healthcare Solutions, INC. | $44.75 | 2020-2024 | Libtayo |
| Merck Sharp & Dohme LLC | $41.44 | 2022-2023 | Keytruda |
| Telix Pharmaceuticals | $39.93 | 2024 | Illuccix |
| Blue Earth Diagnostics | $36.25 | 2019 | |
| Lilly USA, LLC | $31.67 | 2024 | Verzenio |
| Astrazeneca Pharmaceuticals LP | $29.58 | 2024 | Tagrisso |
| Abbvie INC. | $28.83 | 2024 | |
| Sobi, INC | $27.25 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $25.21 | 2022 | |
| Incyte Corporation | $25.19 | 2024 | Jakafi |
| Servier Pharmaceuticals LLC | $21.32 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Dardick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.